We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+17.02%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
Cap. Flow
+$41.9M
Cap. Flow %
2.06%
Top 10 Hldgs %
54.88%
Holding
72
New
11
Increased
1
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$19.9M
2
QURE icon
uniQure
QURE
+$14.5M
3
NRIX icon
Nurix Therapeutics
NRIX
+$12.8M
4
APGE icon
Apogee Therapeutics
APGE
+$8.58M
5
TIL icon
Instil Bio
TIL
+$8.37M

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$12.7M
2
ALLO icon
Allogene Therapeutics
ALLO
+$8.97M
3
NKTX icon
Nkarta
NKTX
+$8.97M
4
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$7.66M
5
PRLD icon
Prelude Therapeutics
PRLD
+$3.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$39.6B
$194M 9.52%
4,279,464
– –
TYRA icon
2
Tyra Biosciences
TYRA
$1.91B
$152M 7.44%
6,448,359
– –
NUVL
3
DELISTED
Nuvalent
NUVL
$115M 5.62%
1,120,192
– –
ONC
4
BeOne Medicines Ltd
ONC
$32.4B
$112M 5.51%
500,000
– –
CYTK icon
5
Cytokinetics
CYTK
$10.9B
$111M 5.44%
2,100,000
– –
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$110M 5.38%
3,421,541
– –
MRUS
7
DELISTED
Merus
MRUS
$94.9M 4.66%
1,900,000
– –
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.82B
$81.2M 3.98%
650,000
– –
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$79.3M 3.89%
1,727,388
– –
IDYA icon
10
IDEAYA Biosciences
IDYA
$3.47B
$69.8M 3.42%
2,202,812
– –
TNGX icon
11
Tango Therapeutics
TNGX
$4.65B
$63.1M 3.1%
8,198,642
– –
ARGX icon
12
argenx
ARGX
$53.8B
$54.2M 2.66%
100,000
– –
APLS
13
DELISTED
Apellis Pharmaceuticals
APLS
$49.8M 2.44%
1,726,000
– –
AKRO
14
DELISTED
Akero Therapeutics
AKRO
$48.1M 2.36%
1,676,733
– –
ANAB icon
15
AnaptysBio
ANAB
$1.72B
$43.5M 2.14%
1,300,000
– –
AXSM icon
16
Axsome Therapeutics
AXSM
$11.8B
$35.9M 1.76%
400,000
– –
ITOS
17
DELISTED
iTeos Therapeutics
ITOS
$30.1M 1.48%
2,946,915
– –
LEGN icon
18
Legend Biotech
LEGN
$4.31B
$29.2M 1.43%
600,000
– –
GERN icon
19
Geron
GERN
$924M
$27.2M 1.34%
6,000,000
– –
THRD
20
DELISTED
Third Harmonic Bio
THRD
$27.1M 1.33%
2,000,000
– –
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$376M
$27.1M 1.33%
1,466,051
– –
RCUS icon
22
Arcus Biosciences
RCUS
$3.44B
$24.5M 1.2%
1,602,200
– –
TIL icon
23
Instil Bio
TIL
$50.3M
$23.9M 1.17%
+355,500
New +$8.37M
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.6B
$23.6M 1.16%
600,000
– –
IMVT icon
25
Immunovant
IMVT
$8.27B
$23.5M 1.15%
825,000
– –
1
2 3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Boxer Capital held 72 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Boxer Capital's Q3 2024 filing shows 11 new, 1 increased, 5 reduced and 4 closed positions. Its largest new stake was Kymera Therapeutics: 450,000 shares worth $21.3M. The largest sale was Fate Therapeutics, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Boxer Capital's largest Q3 2024 buy was Kymera Therapeutics: 450,000 shares worth $21.3M.
  • Boxer Capital added most to Cullinan Oncology in Q3 2024, an estimated $4.43M increase.
  • Boxer Capital's biggest Q3 2024 reduction was Fate Therapeutics, cutting an estimated $12.7M.
  • Boxer Capital fully exited Allogene Therapeutics in Q3 2024, selling an estimated $8.97M.
  • Boxer Capital's ten largest holdings make up 55% of its $2.04B portfolio in Q3 2024.
  • Boxer Capital opened 11 new positions and closed 4 in Q3 2024.
  • Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.

Based on Boxer Capital's 13F filing for Q3 2024, filed 14 Nov 2024.